

## Leading Alzheimer's Researchers to Address Shareholders

- **Professor Ralph Martins**, a pioneer in Alzheimer's disease research, and **Associate Professor Kathryn Goozee**, a neurological research specialist, to address shareholders following Actinogen's Annual General Meeting (AGM) on 29<sup>th</sup> November
- Professor Martins and Associate Professor Goozee are co-founders of **KaRa Minds**, a leading neurological institute that is one of the leading Australian clinical trial sites for **XanADu**
- KaRa Minds is one of the highest enrolling trial sites for **XanADu**, Actinogen's clinical trial of Xanamem in Alzheimer's disease

**Sydney, 22 November 2017: Actinogen Medical (ASX: ACW)** is pleased to announce that **Professor Ralph Martins and Associate Professor Kathryn Goozee**, directors of **KaRa Minds**, one of the leading sites for patient enrolment into Actinogen's **XanADu** Alzheimer's trial, will address shareholders following the Actinogen AGM on 29<sup>th</sup> November.

Widely respected as one of the leading international researchers into Alzheimer's disease, Professor Martins has been working in the field for more than 30 years and is well-known and highly respected both nationally and internationally. Over the last 30 years, his insight into this devastating disease has led to many ground-breaking discoveries. He contributed to the pioneering discovery of Beta-amyloid (A $\beta$ ) and the amyloid precursor protein (APP), important proteins found in the brains of Alzheimer's patients now universally acknowledged as being fundamental to the pathology of Alzheimer's disease.

Associate Professor Kathryn Goozee has more than 30 years of clinical experience encompassing management, education and care. Within the last decade, she has broadened her focus to encompass applied clinical research with a particular focus on Alzheimer's disease prevention.

Professor Martins and Associate Professor Goozee are Co-Founders and Directors of **KaRa Minds (KaRa Institute of Neurological Disease)**, whose mission is to facilitate high-calibre neurological clinical trials which will ultimately translate discovery into improved diagnostics and better care. KaRa Minds promotes biomedical and clinical research and undertakes high-impact studies, one of which is XanADu - Actinogen Medical's Phase II study investigating Xanamem in patients with mild dementia due to Alzheimer's disease.

"KaRa Minds is about finding solutions to those medical questions that remain unanswered. Xanamem has the potential to answer one of the most medically important issues of our time: developing new effective treatments for Alzheimer's disease. It is with much enthusiasm that Kathryn and I, and the KaRa clinical team, are involved in XanADu, and we look forward to sharing our thoughts on Xanamem, and our experience to date in recruiting patients into the XanADu trial, with Actinogen shareholders," said Professor Martins.

"Actinogen is delighted to have two Alzheimer's experts of the calibre of Professor Martins and Associate Professor Goozee addressing our shareholders this year. As the KaRa Minds research site is one of the most active in our XanADu clinical trial, they'll be able to provide immense insight into the operations and conduct of the trial, and into Alzheimer's clinical research in general." said Dr Bill Ketelbey, CEO of Actinogen Medical.

**ENDS**

## **Actinogen Medical**

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: [bill.ketelbey@actinogen.com.au](mailto:bill.ketelbey@actinogen.com.au)

 @BillKetelbey

## **About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

## **About Xanamem™**

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

## **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**